Aspirin and nonsteroidal anti-inflammatory drug hypersensitivity

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Acetylsalicylic acid (ASA) or aspirin and nonsteroidal anti-inflammatory drug (NSAID) sensitivities encompass a diverse group of both pharmacological and hypersensitivity reactions. Conventionally, hypersensitivities include aspirin-exacerbated respiratory disease (AERD), ASA-induced urticaria, and anaphylaxis. With an increasing prevalence of coronary artery disease in an aging population, aspirin continues to play a significant role in cardiac prophylaxis in a large patient population. Invariably, the clinician will encounter patients with clear indications for aspirin therapy but a history of aspirin sensitivity. Although protocols have been established for aspirin challenge and desensitization, it is not always an efficacious or safe procedure. This article reviews the different classifications of ASA/NSAIDs hypersensitivities to better guide the clinician in dealing with this patient population. History of crossrelativities between multiple NSAIDs implies a non-IgE-mediated process. Similarly, a history of monosensitivity to one NSAID implies an IgE-mediated process, although specific antibodies are often elusive. Despite the name, AERD can potentially be exacerbated by all cyclooxygenase (COX) inhibitors based on dose-dependent inhibition of COX-1. Aspirin desensitization can be achieved to improve both upper and lower respiratory symptoms for most patient with AERD. Aspirin desensitization can usually be achieved for those in need of the antiplatelet effects of aspirin, with the exception of those with aspirin-induced urticaria and baseline chronic urticaria. However, desensitization should only be attempted in those with stable coronary artery disease because the process of desensitization carries the inherent risk of anaphylaxis/anaphylactoid reaction, which may further increase cardiac demand and bring about ischemic injury. Therefore, desensitization is reserved until coronary artery disease is stabilized.

Original languageEnglish (US)
Pages (from-to)97-109
Number of pages13
JournalClinical Reviews in Allergy and Immunology
Volume32
Issue number1
DOIs
StatePublished - Feb 2007

Fingerprint

Drug Hypersensitivity
Aspirin
Anti-Inflammatory Agents
Urticaria
Coronary Artery Disease
Hypersensitivity
Anaphylaxis
Non-Steroidal Anti-Inflammatory Agents
Population
Cyclooxygenase 1
Cyclooxygenase Inhibitors

Keywords

  • Adverse events
  • Anaphylactoid
  • Anaphylaxis
  • Angioedema
  • Arachadonic acid
  • Aspirin
  • Aspirin exacerbated respiratory disease
  • Cyclooxygenases
  • Hypersensitivity
  • Leukotrienes
  • Nonsteroidal anti-inflammatory drugs
  • Sensitivity
  • Urticaria

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Aspirin and nonsteroidal anti-inflammatory drug hypersensitivity. / Kong, James S W; Teuber, Suzanne S; Gershwin, M. Eric.

In: Clinical Reviews in Allergy and Immunology, Vol. 32, No. 1, 02.2007, p. 97-109.

Research output: Contribution to journalArticle

@article{546d5547138c404e89c53b6dea1d5a22,
title = "Aspirin and nonsteroidal anti-inflammatory drug hypersensitivity",
abstract = "Acetylsalicylic acid (ASA) or aspirin and nonsteroidal anti-inflammatory drug (NSAID) sensitivities encompass a diverse group of both pharmacological and hypersensitivity reactions. Conventionally, hypersensitivities include aspirin-exacerbated respiratory disease (AERD), ASA-induced urticaria, and anaphylaxis. With an increasing prevalence of coronary artery disease in an aging population, aspirin continues to play a significant role in cardiac prophylaxis in a large patient population. Invariably, the clinician will encounter patients with clear indications for aspirin therapy but a history of aspirin sensitivity. Although protocols have been established for aspirin challenge and desensitization, it is not always an efficacious or safe procedure. This article reviews the different classifications of ASA/NSAIDs hypersensitivities to better guide the clinician in dealing with this patient population. History of crossrelativities between multiple NSAIDs implies a non-IgE-mediated process. Similarly, a history of monosensitivity to one NSAID implies an IgE-mediated process, although specific antibodies are often elusive. Despite the name, AERD can potentially be exacerbated by all cyclooxygenase (COX) inhibitors based on dose-dependent inhibition of COX-1. Aspirin desensitization can be achieved to improve both upper and lower respiratory symptoms for most patient with AERD. Aspirin desensitization can usually be achieved for those in need of the antiplatelet effects of aspirin, with the exception of those with aspirin-induced urticaria and baseline chronic urticaria. However, desensitization should only be attempted in those with stable coronary artery disease because the process of desensitization carries the inherent risk of anaphylaxis/anaphylactoid reaction, which may further increase cardiac demand and bring about ischemic injury. Therefore, desensitization is reserved until coronary artery disease is stabilized.",
keywords = "Adverse events, Anaphylactoid, Anaphylaxis, Angioedema, Arachadonic acid, Aspirin, Aspirin exacerbated respiratory disease, Cyclooxygenases, Hypersensitivity, Leukotrienes, Nonsteroidal anti-inflammatory drugs, Sensitivity, Urticaria",
author = "Kong, {James S W} and Teuber, {Suzanne S} and Gershwin, {M. Eric}",
year = "2007",
month = "2",
doi = "10.1007/s12016-007-0024-9",
language = "English (US)",
volume = "32",
pages = "97--109",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Aspirin and nonsteroidal anti-inflammatory drug hypersensitivity

AU - Kong, James S W

AU - Teuber, Suzanne S

AU - Gershwin, M. Eric

PY - 2007/2

Y1 - 2007/2

N2 - Acetylsalicylic acid (ASA) or aspirin and nonsteroidal anti-inflammatory drug (NSAID) sensitivities encompass a diverse group of both pharmacological and hypersensitivity reactions. Conventionally, hypersensitivities include aspirin-exacerbated respiratory disease (AERD), ASA-induced urticaria, and anaphylaxis. With an increasing prevalence of coronary artery disease in an aging population, aspirin continues to play a significant role in cardiac prophylaxis in a large patient population. Invariably, the clinician will encounter patients with clear indications for aspirin therapy but a history of aspirin sensitivity. Although protocols have been established for aspirin challenge and desensitization, it is not always an efficacious or safe procedure. This article reviews the different classifications of ASA/NSAIDs hypersensitivities to better guide the clinician in dealing with this patient population. History of crossrelativities between multiple NSAIDs implies a non-IgE-mediated process. Similarly, a history of monosensitivity to one NSAID implies an IgE-mediated process, although specific antibodies are often elusive. Despite the name, AERD can potentially be exacerbated by all cyclooxygenase (COX) inhibitors based on dose-dependent inhibition of COX-1. Aspirin desensitization can be achieved to improve both upper and lower respiratory symptoms for most patient with AERD. Aspirin desensitization can usually be achieved for those in need of the antiplatelet effects of aspirin, with the exception of those with aspirin-induced urticaria and baseline chronic urticaria. However, desensitization should only be attempted in those with stable coronary artery disease because the process of desensitization carries the inherent risk of anaphylaxis/anaphylactoid reaction, which may further increase cardiac demand and bring about ischemic injury. Therefore, desensitization is reserved until coronary artery disease is stabilized.

AB - Acetylsalicylic acid (ASA) or aspirin and nonsteroidal anti-inflammatory drug (NSAID) sensitivities encompass a diverse group of both pharmacological and hypersensitivity reactions. Conventionally, hypersensitivities include aspirin-exacerbated respiratory disease (AERD), ASA-induced urticaria, and anaphylaxis. With an increasing prevalence of coronary artery disease in an aging population, aspirin continues to play a significant role in cardiac prophylaxis in a large patient population. Invariably, the clinician will encounter patients with clear indications for aspirin therapy but a history of aspirin sensitivity. Although protocols have been established for aspirin challenge and desensitization, it is not always an efficacious or safe procedure. This article reviews the different classifications of ASA/NSAIDs hypersensitivities to better guide the clinician in dealing with this patient population. History of crossrelativities between multiple NSAIDs implies a non-IgE-mediated process. Similarly, a history of monosensitivity to one NSAID implies an IgE-mediated process, although specific antibodies are often elusive. Despite the name, AERD can potentially be exacerbated by all cyclooxygenase (COX) inhibitors based on dose-dependent inhibition of COX-1. Aspirin desensitization can be achieved to improve both upper and lower respiratory symptoms for most patient with AERD. Aspirin desensitization can usually be achieved for those in need of the antiplatelet effects of aspirin, with the exception of those with aspirin-induced urticaria and baseline chronic urticaria. However, desensitization should only be attempted in those with stable coronary artery disease because the process of desensitization carries the inherent risk of anaphylaxis/anaphylactoid reaction, which may further increase cardiac demand and bring about ischemic injury. Therefore, desensitization is reserved until coronary artery disease is stabilized.

KW - Adverse events

KW - Anaphylactoid

KW - Anaphylaxis

KW - Angioedema

KW - Arachadonic acid

KW - Aspirin

KW - Aspirin exacerbated respiratory disease

KW - Cyclooxygenases

KW - Hypersensitivity

KW - Leukotrienes

KW - Nonsteroidal anti-inflammatory drugs

KW - Sensitivity

KW - Urticaria

UR - http://www.scopus.com/inward/record.url?scp=34247150645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247150645&partnerID=8YFLogxK

U2 - 10.1007/s12016-007-0024-9

DO - 10.1007/s12016-007-0024-9

M3 - Article

C2 - 17426365

AN - SCOPUS:34247150645

VL - 32

SP - 97

EP - 109

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 1

ER -